Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-16-130106
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-29 17:26:35
Reporting Period:
2016-06-27
Filing Date:
2016-06-29
Accepted Time:
2016-06-29 17:26:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178711 Paratek Pharmaceuticals Inc. PRTK Pharmaceutical Preparations (2834) 330960223
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1403748 Omega Fund Iii, L.p. 1 Royal Plaza, Royal Avenue
St. Peter Port
Guernsey, Channel Islands X0 GY1 2HL
No No Yes No
1528382 Omega Fund Iv, L.p. 1 Royal Plaza, Royal Avenue
St. Peter Port
Guernsey, Channel Islands X0 uk
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-06-27 76,923 $13.00 1,187,365 No 4 P Direct
Common Stock Acquisiton 2016-06-27 384,615 $13.00 779,802 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. The Reporting Persons are part of a "group" as defined in Rule 13d-5 promulgated under the Securities Exchange Act of 1934, as amended (which group also includes K/S Danish BioVenture ("Danish BV") and Danish BioVenture General Partner ApS, whose securities are beneficially owned by Clessidra, LLC. This group beneficially owns, in the aggregate, 2,600,410 shares of common stock of the issuer and warrants to purchase an additional6,412 shares of common stock of the issuer.
  2. The reported securities are held in the name of Omega Fund III, L.P. ("Omega III"). The Reporting Person disclaims beneficial ownership of these securities,except to the extent of its pecuniary interest therein.
  3. The reported securities are held in the name of Omega Fund IV, L.P. ("Omega IV"). The Reporting Person disclaims beneficial ownership of these securities,except to the extent of its pecuniary interest therein.